‘‘PART PP—CONFRONTING THE USE OF HEROIN, 
FENTANYL, AND ASSOCIATED SYNTHETIC DRUGS 
‘‘SEC. 
3061. 
GRANTS 
TO 
ADDRESS 
PUBLIC 
SAFETY 
THROUGH IMPROVED FORENSIC LABORA-
TORY DATA. 
‘‘(a) PURPOSE.—The purpose of a grant awarded 
under this section shall be to promote public health by 
assisting a State or unit of local government— 
‘‘(1) establish or improve a surveillance pro-
gram in order to facilitate the seizure of covered 
controlled substances; and 
‘‘(2) carry out the activities described in section 
101 of the STOP Fentanyl Overdoses Act of 2023. 
‘‘(b) ESTABLISHMENT
OF GRANT.—The Attorney 
General, acting through the Director of the Bureau of 
Justice Assistance, may make a grant to a State or unit 
of local government to promote public health by estab-
lishing or improving a surveillance program in order to 
facilitate the seizure of covered controlled substances. 
‘‘(c) ELIGIBLE PROJECTS.— A grant awarded under 
this section shall be used for a program, project, or other 
activity to— 
‘‘(1) reimburse a State, local, or other forensic 
science laboratory for costs associated with testing 
to help address any backlog of untested samples of 
covered controlled substances; 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
‘‘(2) reimburse a State, local, or other forensic 
science laboratory for the procurement of equipment, 
technology, or other support systems; 
‘‘(3) reimburse State, local, or other forensic 
science laboratory for improved, real time data ex-
change with the Centers for Disease Control and 
Prevention on covered controlled substances; and 
‘‘(4) support a State or local health depart-
ments deployed to address the use of covered con-
trolled substances. 
‘‘(d) 
ADDITIONAL
REQUIREMENT.—A 
program, 
project, or other activity pursuant to subsection (c)(2) 
shall require that the State, unit of local government, or 
Tribe demonstrate, to the satisfaction of the Attorney 
General, that any reimbursement would result in improved 
efficiency of laboratory testing and help prevent future 
backlogs. 
‘‘(e) ALLOCATION.— 
‘‘(1) POPULATION
ALLOCATION.—Seventy-five 
percent of the amount made available to carry out 
this section in a fiscal year shall be allocated to each 
State or unit of local government that meets the re-
quirements of section 2802 so that each State or 
unit of local government shall receive an amount 
that bears the same ratio to the 75 percent of the 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
total amount made available to carry out this section 
for that fiscal year as the population of the State or 
unit of local government bears to the population of 
all States or units of local governments. 
‘‘(2) DISCRETIONARY
ALLOCATION.—Twenty- 
five percent of the amount made available to carry 
out this section in a fiscal year shall be allocated 
pursuant to the discretion of the Attorney General 
for competitive grants to States or units of local gov-
ernment with high rates of primary treatment ad-
missions for polysubstance use, including for covered 
controlled substances, for use by State, local, or 
Tribal law enforcement agencies. 
‘‘(3) LIMITATION.—Not less than 60 percent of 
any amounts made available to carry out this section 
shall be awarded for a program, project, or other ac-
tivity under paragraph (1) or (2) of subsection (c). 
‘‘(4) 
MINIMUM
REQUIREMENT.—Notwith-
standing paragraphs (1), (2), and (3), each State re-
ceiving funds shall not receive less than 0.6 percent 
of the amount made available to carry out this sec-
tion in each fiscal year. 
‘‘(f) 
COVERED
CONTROLLED
SUBSTANCE
DE-
FINED.—In this section, the term ‘covered controlled sub-
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
stance’ means heroin, fentanyl, a fentanyl-related sub-
stance, and any associated synthetic drug.’’. 
TITLE II—STEMMING THE 
SUPPLY OF FENTANYL 
SEC. 201. REPORT ON COUNTRIES THAT PRODUCE SYN-
THETIC DRUGS. 
Not later than one year after the date of enactment 
of this Act, the Secretary of State shall submit to the 
Committee on Energy and Commerce of the House of 
Representatives and the Committee on the Judiciary of 
the Senate a report— 
(1) identifying the countries the Secretary de-
termines are the principal producers of synthetic 
drugs trafficked into the United States; 
(2) assessing how and why those countries are 
producing such drugs; and 
(3) describing measures the Secretary plans to 
take to reduce the flow of such drugs into the 
United States. 
SEC. 202. GAO REPORT ON INTERNATIONAL MAIL AND 
CARGO SCREENING. 
Not later than one year after the date of enactment 
of this Act, the Comptroller General of the United States 
shall submit to the Congress a report reviewing the impact 
of High Intensity Drug Trafficking Areas program on il-
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
licit fentanyl and fentanyl-related substances imported 
through international mail and cargo, including discussion 
of the following: 
(1) The volume of fentanyl and fentanyl-related 
substances being imported into the country by 
means of international mail and cargo. 
(2) The potential impact of increased screening 
for illicit fentanyl and fentanyl-related substances 
on— 
(A) deterring drug trafficking in the 
United States; 
(B) interdicting fentanyl and fentanyl-re-
lated substances that were manufactured out-
side of the United States and intended, or at-
tempted, to be imported into the United States; 
(C) the number of Federal criminal pros-
ecutions based on the manufacture, distribu-
tion, or possession of fentanyl or fentanyl-re-
lated substances, disaggregated by demographic 
data, including sex, race, and ethnicity, of the 
offender; 
(D) the charges brought in such prosecu-
tions; 
(E) the impacts of prosecutions on reduc-
ing demand and availability to users; and 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
(F) the development of new fentanyl-re-
lated substances. 
(3) The need for non-invasive technology in 
screening for fentanyl and fentanyl-related sub-
stances, taking into account the findings pursuant to 
paragraphs (1) and (2). 
TITLE III—OVERDOSE PREVEN-
TION AND SUBSTANCE USE 
DISORDER TREATMENT PRO-
GRAMS 
SEC. 301. OPIOID TREATMENT EDUCATION. 
Part D of title V of the Public Health Service Act 
(42 U.S.C. 290dd et seq.) is amended by adding at the 
end the following: 
‘‘SEC. 553. OPIOID TREATMENT EDUCATION. 
‘‘(a) IN
GENERAL.—The Secretary shall award 
grants to States and local governmental entities to provide 
education to stakeholders, including health care providers, 
criminal justice professionals, and substance use disorder 
treatment personnel, on the current state of research on 
treatment for opioid use disorder, including— 
‘‘(1) the use of opioid agonists or partial 
agonists; and 
‘‘(2) the potential benefits of the use of opioid 
agonists or partial agonists for affected individuals. 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
‘‘(b) REPORT.—Not later than one year after the 
date of enactment of the STOP Fentanyl Overdoses Act 
of 2023, the Secretary shall submit a report to the Com-
mittee on Energy and Commerce of the House of Rep-
resentatives and the Committee on Health, Education, 
Labor, and Pensions of the Senate, including the following 
data: 
‘‘(1) The number of people reached by edu-
cational materials funded pursuant to this section. 
‘‘(2) The geographic areas where people re-
ceived such educational materials. 
‘‘(3) The remaining populations and areas tar-
geted for awareness of educational materials, includ-
ing the characteristics of such populations and areas 
such as the type of stakeholder and geographic area. 
‘‘(4) The select outcomes of education funded 
pursuant to this section as determined by the Sec-
retary.’’. 
SEC. 302. STUDY ON NALOXONE ACCESS. 
(a) IN GENERAL.—The Comptroller General of the 
United States shall conduct a study on actions that may 
be taken to ensure appropriate access and affordability of 
naloxone for individuals seeking to purchase naloxone. 
Such study shall address what is known about— 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
(1) coverage of naloxone (in any available 
form), including whether naloxone can be covered as 
an over-the-counter drug under a group health plan 
or group or individual health insurance coverage (as 
such terms are defined in section 2791 of the Public 
Health Service Act (42 U.S.C. 300gg–91)) or for in-
dividuals entitled to benefits under part A or en-
rolled under part B of title XVIII of the Social Se-
curity Act (42 U.S.C. 1395 et seq.) or receiving 
medical assistance under a State plan under title 
XIX of such Act (42 U.S.C. 1396 et seq.) or a waiv-
er of such plan; 
(2) the out-of-pocket cost to consumers pur-
chasing naloxone— 
(A) with a prescription, with and without 
coverage under any such plan or coverage; 
(B) over-the-counter, with and without cov-
erage under any such plan or coverage; and 
(C) pursuant to a standing order; and 
(3) other factors impacting coverage, including 
barriers in covering naloxone as an over-the-counter 
drug, the relative net costs of naloxone when pur-
chased over-the-counter without insurance coverage 
compared to when purchased with a prescription and 
covered under a group health plan or health insur-
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
ance coverage, and the availability of naloxone pur-
chased and distributed through public health enti-
ties. 
(b) REPORT.—Not later than 2 years after the date 
of the enactment of this Act, the Comptroller General of 
the United States shall submit to Congress a report that 
contains the findings of the study conducted under sub-
section (a). 
SEC. 303. INCREASING ACCESS TO MEDICATION FOR 
OPIOID OVERDOSE REVERSAL. 
(a) TRANSACTIONS.—Section 581(24)(B) of the Fed-
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
360eee(24)(B)) is amended— 
(1) by redesignating clauses (xvii) and (xviii) as 
clauses (xviii) and (xix), respectively; and 
(2) by inserting after clause (xvi) the following: 
‘‘(xvii) the distribution of an opioid 
antagonist indicated for emergency treat-
ment of opioid overdose, such as naloxone, 
by or to an overdose prevention, syringe 
services program, or other harm reduction 
service;’’. 
(b) WHOLESALE DISTRIBUTION.—Section 503(e)(4) 
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
353(e)(4)) is amended— 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
(1) by redesignating subparagraphs (R) and (S) 
as subparagraphs (S) and (T), respectively; and 
(2) by inserting after subparagraph (Q) the fol-
lowing: 
‘‘(R) the distribution of an opioid antago-
nist indicated for emergency treatment of opioid 
overdose, such as naloxone, by or to an over-
dose prevention, syringe services program, or 
other harm reduction service;’’. 
SEC. 304. GRANT PROGRAM ON HARMS OF DRUG MISUSE. 
Part D of title V of the Public Health Service Act 
(42 U.S.C. 290dd et seq.), as amended by section 301, 
is further amended by adding at the end the following: 
‘‘SEC. 554. GRANT PROGRAM ON HARMS OF DRUG MISUSE. 
‘‘(a) IN GENERAL.—The Assistant Secretary, in con-
sultation with the Director of the Centers for Disease Con-
trol and Prevention, shall award grants to States and po-
litical subdivisions of States to support the delivery of 
overdose prevention services, including distribution of 
Food and Drug Administration-approved opioid reversal 
agents such as naloxone, fentanyl strips, and other harm 
reduction services that address the harms of drug misuse, 
including by— 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
‘‘(1) connecting individuals at risk for, or with, 
a substance use disorder to overdose education, 
counseling, and health education; and 
‘‘(2) encouraging such individuals to take steps 
to reduce the harms associated with substance mis-
use. 
‘‘(b) CONSIDERATIONS.—In awarding grants under 
this section, the Assistant Secretary shall prioritize grants 
to applicants that are— 
‘‘(1) organizations providing culturally com-
petent care in terms of considerations based on race, 
language, ethnicity, gender, sexuality, or disability; 
or 
‘‘(2) proposing to serve areas with— 
‘‘(A) a higher proportion of the population 
who meet criteria for dependence on, or abuse 
of, illicit drugs; 
‘‘(B) a higher drug overdose death rate; 
and 
‘‘(C) a greater behavioral health and sub-
stance use disorder workforce need. 
‘‘(c) SPECIAL CONSIDERATIONS.—A recipient of a 
grant under this section for the purposes described in sub-
section (a)(2) shall provide overdose prevention services, 
as follows: 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
‘‘(1) Ensure that not less than 60 percent of 
the grant funds are used for harm reduction pro-
grams. 
‘‘(2) Prioritize the delivery of opioid antagonists 
to— 
‘‘(A) people who use opioids or illicit 
drugs; 
‘‘(B) families of such people; 
‘‘(C) first responders such as law enforce-
ment personnel and nonemergency services such 
as fire fighters and park rangers; and 
‘‘(D) community service providers, such as 
library, school, and public transportation per-
sonnel. 
‘‘(d) USE OF GRANT AWARDS.—A recipient of a 
grant under this section may use grant funds for the fol-
lowing: 
‘‘(1) Adapting, maintaining, and expanding es-
sential services provided by harm reduction service 
organizations to address the risks of drug overdose 
and contraction of infectious disease. 
‘‘(2) Maintaining or hiring staff. 
‘‘(3) Supporting program operational costs, in-
cluding staff, rent, and vehicle purchase or mainte-
nance. 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
‘‘(4) Program supplies. 
‘‘(5) Support and case management services.’’. 
SEC. 305. GOOD SAMARITAN IMMUNITY. 
(a) IN GENERAL.—Part B of title II of the Public 
Health Service Act is amended by inserting after section 
248 of such Act (42 U.S.C. 238q) the following: 
‘‘SEC. 249. GOOD SAMARITAN IMMUNITY. 
‘‘(a) LIMITATION ON CIVIL LIABILITY FOR INDIVID-
UALS WHO ADMINISTER OPIOID OVERDOSE REVERSAL 
DRUGS.— 
‘‘(1) IN GENERAL.—Notwithstanding any other 
provision of law, except as provided in paragraph 
(2), no individual shall be liable in any Federal or 
State proceeding for harm caused by the emergency 
administration of an opioid overdose reversal drug to 
an individual who has or reasonably appears to have 
suffered an overdose from heroin or another opioid, 
if the individual who administers the opioid overdose 
reversal drug does so in good faith. 
‘‘(2) EXCEPTION.—Paragraph (1) shall not 
apply to an individual if the harm was caused by the 
gross negligence or reckless misconduct of the indi-
vidual who administers the drug. 
‘‘(3) DEFINITIONS.—In this subsection: 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
‘‘(A) The term ‘health care professional’ 
means a person licensed by a State to prescribe 
prescription drugs. 
‘‘(B) The term ‘opioid overdose reversal 
drug’ means a drug approved under section 505 
of the Federal Food, Drug, and Cosmetic Act 
that is indicated for the partial or complete re-
versal of the pharmacological effects of an 
opioid overdose in the human body. 
‘‘(C) The term ‘opioid overdose prevention 
program’ means a program operated by a local 
health department, harm reduction or other 
community-based organization, substance abuse 
treatment organization, law enforcement agen-
cy, fire department, other first responder de-
partment, or voluntary association, or a pro-
gram funded by a Federal, State, or local gov-
ernment, that works to prevent opioid overdoses 
by in part providing opioid overdose reversal 
drugs and education— 
‘‘(i) to individuals at risk of experi-
encing an opioid overdose; or 
‘‘(ii) to an individual in a position to 
assist another individual at risk of experi-
encing an opioid overdose. 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
‘‘(b) IMMUNITY FROM LIABILITY.— 
‘‘(1) IN GENERAL.—An individual who, in good 
faith and in a timely manner— 
‘‘(A) seeks medical assistance for another 
individual who is experiencing a drug overdose, 
or 
‘‘(B) seeks medical assistance for himself 
or herself for a drug overdose, or is the subject 
of a request for medical assistance described in 
subparagraph (A), 
shall not be cited, arrested, prosecuted, criminally 
liable, or subject to any sanction for a violation of 
a condition of supervised release under section 404 
of the Controlled Substances Act for the possession 
or use of a controlled substance, or under any other 
provision of Federal law regulating the misuse of 
prescription drugs, as a result of seeking such med-
ical assistance. 
‘‘(2) PREEMPTION.—This subsection preempts 
the laws of a State or any political subdivision of a 
State to the extent that such laws are inconsistent 
with this section, unless such laws provide greater 
protection from liability. 
‘‘(3) DEFINITIONS.—In this section: 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
‘‘(A) The term ‘controlled substance’ has 
the meaning given the term in section 102 of 
the Controlled Substances Act. 
‘‘(B) The term ‘drug overdose’ means an 
acute condition resulting from or believed to be 
resulting from the use of a controlled sub-
stance, which an individual, who is not a health 
care professional, would reasonably believe re-
quires medical assistance. 
‘‘(C) The term ‘prescription drug’ means a 
drug subject to section 503(b)(1) of the Federal 
Food, Drug, and Cosmetic Act. 
‘‘(D) The terms ‘seeks medical assistance’ 
and ‘seeking such medical assistance’ include— 
‘‘(i) reporting a drug or alcohol over-
dose or other medical emergency to a law 
enforcement authority, the 9–1–1 system, 
a poison control center, or a medical pro-
vider; 
‘‘(ii) assisting another individual who 
is making a report described in clause (i); 
or 
‘‘(iii) providing care to someone who 
is experiencing a drug or alcohol overdose 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS
or other medical emergency while awaiting 
the arrival of medical assistance.’’. 
(b) PUBLIC AWARENESS CAMPAIGN.—The Secretary 
of Health and Human Services, in coordination with the 
Administrator of the Drug Enforcement Administration, 
shall carry out a campaign to increase public awareness 
of the limitations on civil and criminal liability established 
by section 249 of the Public Health Service Act, as added 
by subsection (a). 
SEC. 306. REPORT ON OVERDOSE PREVENTION CENTERS. 
The Secretary of Health and Human Services shall 
enter into appropriate arrangements with the National 
Academies of Sciences, Engineering, and Medicine under 
which the Academies agree to— 
(1) not later than two years after the date of 
enactment of this Act, submit to the Congress a re-
port on overdose prevention centers; and 
(2) include in such report— 
(A) identification of barriers to operating 
overdose prevention centers; 
(B) a compilation of the data available to 
measure effectiveness of overdose prevention 
centers on reducing overdose deaths, and im-
proving access to medication for opioid use dis-
order and recovery services; 
VerDate Sep 11 2014 
04:19 May 31, 2023
Jkt 039200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6201
E:\BILLS\H3375.IH
H3375
kjohnson on DSK79L0C42PROD with BILLS